Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

TERN-601

DISCONTINUED

Oral non-peptide GLP-1 receptor agonist

4
graded results
0
ongoing records
3
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 3

TERN-601 has a discontinued status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

DISCONTINUED Global programme; Obesity; Oral tablet; as of 2026-07-13. Terns Pharmaceuticals

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 DISCONTINUED
weight-loss Decrease
Low evidence

Oral non-peptide GLP-1RA (Terns Pharmaceuticals). Phase 1 SAD/MAD in healthy adults with obesity/overweight reported dose-dependent placebo-adjusted weight loss up to...

Terns Pharmaceuticals press Sept 2024; ADA 85th Scientific Sessions June 2025 Source
Full findingOral non-peptide GLP-1RA (Terns Pharmaceuticals). Phase 1 SAD/MAD in healthy adults with obesity/overweight reported dose-dependent placebo-adjusted weight loss up to 4.9% at 740 mg once daily over 28 days; 67% lost >=5% at top dose; >95% TEAEs mild. Phase 2 FALCON ongoing (12-week primary endpoint).
PopulationPhase 1 randomised double-blind placebo-controlled SAD/MAD in healthy adults with obesity/overweight; phase 2 FALCON ongoing
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Comparatorsplacebo
TERN-601 DISCONTINUED
weight-loss Decrease
Very low evidence

FALCON phase 2 (12-week topline): modest placebo-adjusted weight loss; program subsequently discontinued.

Terns Pharmaceuticals press release: Topline 12-week data from Phase 2 trial of oral GLP-... Source
PopulationFALCON phase 2 RCT, US multicentre, adults with obesity/overweight without diabetes; n=30 per active cohort + placebo; 12-wk topline
Fundingindustry - Terns
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 DISCONTINUED
safety-other Increase
Very low evidence

Reversible grade-3 liver enzyme elevations in the phase 2 follow-up period.

Terns Pharmaceuticals press release, 21 Oct 2025. Source
PopulationFALCON phase 2 (obesity/overweight); post-treatment follow-up
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
TERN-601 DISCONTINUED
Stomach and gut Increase
Very low evidence

AE-related discontinuation in phase 2 higher than the favourable phase 1 profile suggested.

Terns Pharmaceuticals press release, 21 Oct 2025. Source
PopulationFALCON phase 2 (n=30 per active cohort + placebo)
Fundingindustry - Terns (trial sponsor; inferred from registration trial)
Comparatorsplacebo